Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-Release Naltrexone for Opioid Overdose Prevention in People Using Stimulants
NCT06633900Phase 3Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naltrexone in opioid overdose (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Acceptability at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
naltrexone
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT06633900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633900.